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Abstract
Objectives (a) To evaluate the diagnostic accuracy of anti-TNF trough levels to predict mucosal healing in inflammatory 
bowel disease (IBD); (b) to determine the best cut-off point to predict mucosal healing in IBD patients treated with anti-TNF.
Methods This is a multicenter, prospective study. IBD patients under anti-TNF treatment for at least 6 months that had to 
undergo an endoscopy were included. Mucosal healing was defined as: Simple endoscopic score for Crohn’s Disease < 3 
for Crohn’s disease (CD), Rutgeerts score < i2 for CD in postoperative setting, or Mayo endoscopic score ≤ 1 for ulcerative 
colitis (UC). Anti-TNF concentrations were measured using SMART ELISAs at trough.
Results A total of 182 patients were included. Anti-TNF trough levels were significantly higher among patients that had 
mucosal healing than among those who did not. The area under the curve of infliximab for mucosal healing was 0.63 (best 
cutoff value 3.4 μg/mL), and for adalimumab 0.60 (best cutoff value 7.2 μg/mL). In the multivariate analysis, having anti-
TNF drug levels above the cutoff values [odds ratio (OR) 3.1]) and having UC instead of CD (OR 4) were associated with a 
higher probability of having mucosal healing. Additionally, the need for an escalated dosage (OR 0.2) and current smoking 
habit (OR 0.2) were also associated with a lower probability of mucosal healing.
Conclusions There was an association between anti-TNF trough levels and mucosal healing in IBD patients; however, the 
accuracy of the determination of infliximab and adalimumab concentrations able to predict mucosal healing was suboptimal.
Keywords Anti-TNF · Tumor necrosis factor alpha · Trough levels · Mucosal healing · Infliximab · Adalimumab · 
Inflammatory bowel disease · Crohn’s disease · Ulcerative colitis
Abbreviations
IBD  Inflammatory bowel disease
CD  Crohn’s disease
UC  Ulcerative colitis
OR  Odds ratio
anti-TNF  Anti-tumor necrosis factor
SD  Standard deviation
95% CI  95% confidence interval
ROC  Receiver operating characteristic curve
AUC  Area under the curve
PPV  Positive predictive value
NPV  Negative predictive value
Introduction
Approximately two-thirds of patients with inflammatory 
bowel disease (IBD) initially respond to treatment with 
anti-tumor necrosis factor (anti-TNF) drugs. However, effi-
cacy is not sustained over time, since a relevant proportion 
of patients lose the response. It has been estimated in sev-
eral studies that 25–40% of the patients who present ini-
tial response to infliximab subsequently lose it, requiring a 
change in therapy or a dose adjustment [1–3].
María Chaparro and Javier P. Gisbert are both the guarantors of 
the article.
 * María Chaparro 
 mariachs2005@gmail.com
Extended author information available on the last page of the article
 Digestive Diseases and Sciences
1 3
Serum concentration of the anti-TNF drug is one of the fac-
tors that could be more relevant in loss of response phenomena 
[4]. Given that its true clinical utility has not been established 
yet, measurement of anti-TNF drug levels is not routinely 
performed in clinical practice. Two clinical scenarios have 
been proposed in which this measurement might be relevant. 
First, treatment with anti-TNF drugs adjusted for drug levels 
could improve both the duration of response and the safety 
and cost-effectiveness of the treatment. However, results from 
both TAXIT and TAILORIX trials failed to show a consist-
ent clinical benefit from the adjustment of treatment based on 
drug levels, although this strategy led to a more efficient use 
of the drug [5, 6]. Nevertheless, cutoff values for therapeutic 
or subtherapeutic levels of anti-TNF drugs were established 
based only on clinical—but not endoscopic—activity evalua-
tion. Second, therapeutic drug monitoring of anti-TNF drugs 
is useful in the case of loss of response to treatment [7, 8].
Although the strategy to optimize treatment with anti-TNF 
drugs seems a promising tool to improve the effectiveness and 
efficiency of these drugs, its use in IBD is limited. This is due 
to several causes: a) heterogeneity of measurement methods; 
b) difficulty in interpreting test results because therapeutic cut-
off points are not defined; and c) controversial evidence about 
its efficacy and efficiency in clinical practice [9, 10].
As mentioned above, identification of anti-TNF cutoff 
values is crucial. Initially, trials applied the limit of detection 
of the assay as a pragmatic cutoff value. Further investiga-
tions proposed new cutoff values considering clinical activity. 
Although clinical remission has been considered as a major 
goal of therapy in the treatment of IBD, in recent years endo-
scopic remission—mucosal healing—has been proposed as a 
measure of treatment success [11]. In fact, the incongruence 
between primarily symptom-based disease activity indexes and 
objective measures of inflammation has recently led the regu-
latory agencies to request for documentation showing efficacy 
by objective measures to approve a new drug.
Thus, given the importance of mucosal healing and the 
demonstrated benefits of therapeutic drug monitoring in the 
use of anti-TNF therapy, together with the paucity of infor-
mation about the correlation between anti-TNF drug levels 
and mucosal healing, we performed the present study aiming 
to know the correlation between anti-TNF drug levels and 
mucosal healing. In addition, we aimed to define the optimal 
drug level required to have the highest probability of achiev-
ing mucosal healing.
Methods
Patients
One hundred eighty-two consecutive patients diagnosed 
with Crohn’s disease (CD) or ulcerative colitis (UC) based 
on clinical, radiological, endoscopic, and histological eval-
uations were included. Patients were under anti-TNF treat-
ment in stable doses for at least 6 months and underwent 
a colonoscopy due to clinical practice. Exclusion criteria 
were as follows: to have CD affecting intestinal segments 
not accessible to endoscopy; to have an incomplete endo-
scopic examination (an incomplete ileocolonoscopy in 
CD or incomplete colonoscopy in UC); to have received 
anti-TNF only for perianal disease; or to be treated with 
anti-TNF for prophylaxis of postoperative CD recurrence 
or pouchitis. However, CD patients treated with anti-TNF 
drugs for active postoperative recurrence were allowed for 
inclusion. The study was approved by the Research Ethics 
Committee of the Hospital Universitario de La Princesa 
(Madrid, Spain).
Study Design
We conducted a prospective, multicenter cohort study; 
sixteen IBD units across Spain participated in this pro-
ject. Clinical and endoscopic evaluation was assessed, and 
blood samples were obtained just before the administra-
tion of the drug (trough levels) within a month after the 
endoscopic evaluation. The principal variable was mucosal 
healing (see Endoscopic activity assessment section for 
definition).
Data Collection
Data were prospectively obtained from medical records. 
Variables included in the database were as follows: IBD 
type (location and behavior), age at diagnosis of IBD, time 
of evolution of the disease, smoking habit, surgical interven-
tions due to IBD, concomitant treatment with immunosup-
pressants, previous treatment with anti-TNF drugs, type of 
anti-TNF drug, anti-TNF dosage (standard or optimized), 
and clinical and endoscopic activity.
Study data were collected and managed using the RED-
Cap electronic data capture tool hosted at Asociación Espa-
ñola de Gastroenterología (AEG; http://www.aegas tro.
es) [12]. AEG is a nonprofit scientific and medical society 
focused on gastroenterology, and it provides this service 
free of charge, with the sole aim of promoting independent 
investigator-driven research. REDCap (Research Electronic 
Data Capture) is a secure, Web-based application designed 
to support data capture for research studies, providing: (1) 
an intuitive interface for validated data entry; (2) audit trails 
for tracking data manipulation and export procedures; (3) 
automated export procedures for seamless data downloads to 
common statistical packages; and (4) procedures for import-
ing data from external sources.
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Endoscopic Activity Assessment
The calculation of endoscopic activity was based on the 
Mayo index for UC, Simple endoscopic score for CD (SES-
CD) for CD [13] in patients without intestinal resection, 
and Rutgeerts score in CD patients with ileocolic resection 
[14]. Mucosal healing was defined as a SES-CD < 3 for CD 
patients, Rutgeerts score < i2 for CD patients in the postop-
erative setting, or Mayo endoscopic score < 2 for UC patients 
[15].
All endoscopists were blinded to clinical assessment, bio-
logical data, and the anti-TNF trough level measurement.
Samples
Blood samples were obtained in 10-mL biochemical 
tubes. The time elapsed between the analytical determina-
tion and the completion of the endoscopy did not exceed 
30  days.  Each 10-mL tube was centrifuged for 10  min 
(3000 rpm at 25 °C), and the supernatant cryopreserved 
following the kit manufacturer’s instructions at a maxi-
mum temperature of − 20 °C until centrally analyzed by 
SMART ELISAs in Sanquin Laboratories (Amsterdam, The 
Netherlands).
Statistical Analysis
Quantitative variables were expressed as mean and standard 
deviation (SD) or median and interquartile range, depending 
on whether or not they followed a normal distribution. Qual-
itative variables were expressed as frequencies with their 
95% confidence intervals (95% CI).
In the univariate analysis, variables were compared con-
sidering the presence of mucosal healing as the dependent 
variable. Qualitative variables were compared using the 
Chi-square test. The quantitative variables were compared 
by the Student’s t test or a nonparametric test in the case of 
variables that did not follow a normal distribution.
In the main analysis, a receiver operating characteris-
tic curve (ROC) analysis was performed using mucosal 
healing as classification variable, and area under the ROC 
(AUC) was determined for both adalimumab and inflixi-
mab. The optimal cutoff point (“therapeutic drug level”), 
for each anti-TNF drug (adalimumab and infliximab) was 
selected. Sensitivity, specificity, positive predictive value 
(PPV), and negative predictive value (NPV) were calcu-
lated for the selected cutoff point. In the next step, inflixi-
mab and adalimumab concentrations were recoded as a 
categorical variable named “Drug level” according to the 
cutoff concentration selected for each drug considering 
the ROC. Drug level was considered positive (equal to or 
above the cutoff) or negative (below the cutoff). Variables 
associated with mucosal healing in the univariate analysis 
were combined in a stepwise multivariate logistic regres-
sion model to identify variables independently associ-
ated with mucosal healing. For this analysis, the variable 
“Drug level” was considered, instead of the drug con-
centration, to evaluate the influence of anti-TNF levels 
(infliximab together with adalimumab) in mucosal heal-
ing. In addition, the same model was repeated including 
infliximab and adalimumab concentrations separately, to 
analyze the impact of changes in the anti-TNF concentra-
tion in the probability of having mucosal healing.
Results
A total of 182 patients were included in the study. Of them, 
92 (50.5%) were male, 94 (51%) were under adalimumab 
treatment, and 88 (48.4%) were under infliximab treatment. 
Among patients treated with infliximab, 37 (42%) were 
under concomitant treatment with immunosuppressants. 
Median infliximab concentration was similar in patients 
with and without immunosuppressants (3.8 vs. 3.4, p = 0.8). 
In addition, 18 patients (20.5%) treated with infliximab 
received an escalated dosage; median infliximab trough level 
was significantly higher in these patients (6.2 vs. 3.4 μg/mL, 
p = 0.03).
Within adalimumab patients, 33 (35%) were under esca-
lated treatment. Median adalimumab concentration was 
slightly higher in patients under escalated dosage than 
in those without dose intensification (9.9 vs. 6.5 μg/mL, 
p = 0.06). In addition, 26 patients treated with adalimumab 
were on concomitant immunosuppressants. Median adali-
mumab concentration was similar in patients with and with-
out concomitant immunosuppressants (6.4 vs. 5.6 μg/mL, 
p = 0.2).
Among the 182 included patients, 93 (51.1%) had 
mucosal healing. The main characteristics of the study pop-
ulation based on the presence of mucosal healing are sum-
marized in Table 1. ROC analysis showing the optimal cutoff 
values of both infliximab and adalimumab trough levels to 
predict mucosal healing is included in Fig. 1. The AUC of 
infliximab to predict mucosal healing was 0.63, and the best 
cutoff point was 3.4 μg/mL. The sensitivity, specificity, PPV, 
and NPV are summarized in Table 2. On the other hand, the 
AUC of adalimumab to predict mucosal healing was 0.60 
and the best cutoff point was 7.2 μg/mL. The sensitivity, 
specificity, PPV, and NPV are summarized in Table 2.
In the univariate analysis, several variables, such as 
tobacco consumption, having CD instead of UC, or previ-
ous infliximab therapy, were significantly associated with 
mucosal healing (Table 3). Of note, median infliximab 
trough levels were significantly higher in patients with 
mucosal healing than in those without mucosal healing (4.8 
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vs. 3 μg/mL, p = 0.03) (Fig. 2). Mean adalimumab trough 
levels were also significantly higher in patients with mucosal 
healing (9.6 vs. 7.1 μg/mL, p = 0.04) (Fig. 2).
In the multivariate analysis, anti-TNF trough levels were 
classified as positive or negative based on the optimal cutoff 
value chosen from the ROCs. In this regard, having anti-
TNF trough levels above the cutoff concentration (OR 3.1, 
95% CI 1.5–6.5) and having UC instead of CD (OR 4.1, 
95% CI 1.7–9.5) were significantly associated with a higher 
probability of mucosal healing. Additionally, smokers and 
patients that needed escalated dosage had lower probability 
of mucosal healing (Table 3).
The model was repeated considering infliximab and adali-
mumab concentration as continuous variables to analyze the 
impact that the change in anti-TNF concentration exerted on 
the probability of having mucosal healing. With respect to 
adalimumab, trough concentration was significantly associ-
ated with higher probability of mucosal healing (OR 1.09, 
95% CI 1.008–1.1). The model confirmed that receiving 
escalated dosage and smoking habit were significantly asso-
ciated with a lower probability of mucosal healing (Table 3).
Infliximab trough levels were also associated with higher 
probability of mucosal healing (OR 1.2, 95% CI 1.01–1.4), 
as well as having UC instead of CD. Conversely, to be 
treated with an escalated dosage and smoking habit were 
significantly associated with lower probability of mucosal 
healing (Table 3).
Anti-drug antibodies were measured only in patients 
with undetectable anti-TNF serum levels. Therefore, it was 
not possible to analyze the effect of anti-drug antibodies on 
anti-TNF serum concentration. A total of 28 patients had 
anti-drug levels below the limit of detection: Of them, 16 
(57%) were also negative for anti-drug antibodies, whereas 
12 (43%) were positive for anti-drug antibodies.
Discussion
To our knowledge, this is the largest prospective study 
designed to assess the correlation between anti-TNF 
trough levels and mucosal healing in IBD patients. We 
found that there is an association between anti-TNF serum 
levels (infliximab and adalimumab) and the presence of 
Table 1  Association of baseline 
characteristics of the study 
population with the presence 
of mucosal healing (univariate 
analysis)
N.S. non-statistically significant, SD standard deviation, IQR interquartile range
Mucosal healing No mucosal healing p
Female gender, n (%) 51 (54.8) 39 (43.8) N.S.
Active smoking, n (%) 11 (11.8) 39 (43.8) < 0.001
Crohn’s disease, n (%) 51 (54.8) 76 (85.4) < 0.001
Location
Ileal 21 (22.6) 28 (31.5) N.S.
Colonic 11 (11.8) 14 (15.7)
Ileocolonic 18 (19.4) 34 (38.2)
Upper gastrointestinal tract 2 (2.2) 2 (2.2)
Behavior
Inflammatory 30 (58.8) 37 (48.7) N.S.
Stricturing 10 (19.6) 24 (31.6)
Fistulizing 11 (21.6) 15 (19.7)
Perianal 36 (70.6) 49 (64.5) N.S.
Ulcerative colitis
Extensive 29 (69) 10 (76.9) N.S.
Left-sided 13 (31) 3 (23.1)
Previous surgery, n (%) 17 (18.3) 32 (36) < 0.01
Drug, infliximab, n (%) 58 (62.4) 30 (33.7) < 0.001
Escalated dosage, n (%) 16 (17.2) 35 (39.3) < 0.01
Previous anti-TNF exposure, n (%) 15 (16) 33 (37) < 0.001
Concomitant immunosuppressants, n (%) 35 (37.6) 28 (31.5) N.S.
Anti-TNF concentration over the threshold, n (%) 58 (62.4) 40 (44.9) 0.01
Age (mean, SD), years 45.3 (14.2) 40.3 (11.4) 0.01
Time of evolution of the disease (mean, SD), months 140.4 (96.3) 143 (94.6) N.S.
Duration of treatment with current anti-TNF (median, 
IQR), months
39 (6–123) 26 (6–110) N.S.
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mucosal healing. We also determined infliximab and adali-
mumab cutoff points to predict mucosal healing. Neverthe-
less, the accuracy of this determination was poor (as the 
areas under the ROCs were below 0.7). This means that 
a relevant proportion of patients would be misclassified 
based on the determination of anti-TNF serum levels.
Based on our results, we proposed a concentration of 
3.4 μg/mL as the best cutoff point for infliximab, and 
7.2 μg/mL for adalimumab. The probability of having 
mucosal healing was threefold higher among patients with 
anti-TNF serum levels over these cutoff values.
Currently, information on the correlation between anti-
TNF levels and the presence of endoscopic lesions is very 
scarce. Up to now, few studies have been published on 
this subject and most of them included a limited number 
of patients. Besides, several of those studies performed 
random measures (instead of trough levels), while many of 
them also used non-validated indexes for the classification 
of endoscopic activity [16–22] (Table 4). Furthermore, the 
concordance between the different assays is low [9, 10]. 
The diagnostic accuracy of anti-TNF levels for mucosal 
healing reported in those studies has been generally poor, 
with AUCs between 0.6 and 0.7 in most cases.
The highest accuracy of anti-TNF levels able to pre-
dict mucosal healing was reported by Morita et al. [22]. 
Authors included 42 patients that underwent a transanal 
enteroscopy with a mean intubation depth from the ileoce-
cal valve of 51 cm (range 15–200 cm). The AUC of adali-
mumab trough levels for mucosal healing was 0.79 (i.e., 
fair), but the precision of this estimation was low, as the 
95% CI of the AUC ranged from 0.65 to 0.93. The adali-
mumab trough level that was best associated with mucosal 
healing was 7.9 μg/mL. However, authors acknowledged 
that the study had several shortcomings such as a limited 
sample size or the use of the modified Rutgeerts scoring 
system to categorize endoscopic activity. The reliability of 
this scoring system has not been confirmed, and its vali-
dation should be performed. Taking all these limitations 
into account, authors suggested that their results should be 
interpreted with caution.
In our study, the best cutoff value for infliximab was 3.4 
μg/mL. This figure is similar to that reported by Reinisch 
et al. [18] and Imaeda et al. [16], which were 3 and 4 μg/mL, 
respectively. On the other hand, Ungar et al. considered that 
therapeutic levels of infliximab were those set at 6–10 μg/
mL [21]. However, blood samples in this retrospective study 
were not obtained at trough, which could explain the higher 
therapeutic range proposed for infliximab concentration.
Fig. 1  Receiver operating characteristic curves (ROCs) showing the 
correlation between infliximab levels (a) or adalimumab levels (b) 
and the presence of mucosal healing
Table 2  Accuracy of anti-
TNF trough serum levels to 
predict mucosal healing in 
inflammatory bowel disease 
patients
AUC area under the ROC, PPV positive predictive value, NPV negative predictive value
Anti-TNF AUC Best cutoff point 
(μg/mL)
Sensitivity 
(%)
Specificity 
(%)
PPV (%) NPV (%)
Infliximab 0.63 3.4 60 60 73 42
Adalimumab 0.60 7.2 65 56 46 72
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The cutoff value for adalimumab is higher than that pro-
posed for infliximab, as reported by most studies. In the 
majority of these studies, including ours, adalimumab cut-
off value was around 8 μg/mL [20–22]. However, the values 
proposed by Roblin and Zittan et al. were lower (around 
4 μg/mL). This is probably due to differences in the defini-
tion of mucosal healing since these authors defined mucosal 
healing just as the absence of ulcers, thereby allowing the 
presence of some inflammatory lesions such as edema, fri-
ability, or erosions.
In addition, in our study we identified several variables 
independently associated with mucosal healing. In this 
respect, having UC instead of CD was associated with a 
higher probability of mucosal healing. Some authors have 
also suggested that severe UC patients might need higher 
load of anti-TNF drugs during the induction [23]. However, 
our study included patients during the maintenance phase. 
CD is a transmural condition, and therefore, this could lead 
to the need of higher amount of drug to block inflammation. 
This observation needs to be confirmed in further studies.
In our study we also found that smoking habit was asso-
ciated with a lower probability of mucosal healing. The 
relationship between smoking habit and poor outcomes in 
CD has been widely demonstrated, meaning higher need for 
surgery, medications, and postsurgical recurrence [24]. In 
our hands, around two-thirds of patients had CD and one-
third had UC. Nevertheless, the variable remained signifi-
cant after adjusting for IBD type in the multivariate analysis. 
Further studies are necessary to confirm whether smokers 
need higher anti-TNF levels to reach mucosal healing.
Finally, in the multivariate analysis, patients under esca-
lated dosage had a lower probability of mucosal healing. Of 
note, dosage had been empirically escalated in our cohort 
Table 3  Factors associated with 
mucosal healing (a) in patients 
under infliximab (b) and 
adalimumab (c) treatment
Odds ratio 95% Confidence 
interval
p
(a) Overall group
 Anti-TNF concentration over the cutoff 3.1 1.5–6.5 0.002
 Optimized anti-TNF dosage 0.2 0.08–0.4 < 0.001
 Ulcerative colitis (vs. Crohn’s disease) 4.1 1.7–9.5 0.001
 Smoking habit 0.2 0.09–0.5 0.001
(b) Infliximab
 Infliximab trough levels (μg/mL) 1.2 1.01–1.4 0.03
 Optimized dosage of infliximab 0.1 0.04–0.6 0.01
 Ulcerative colitis (vs. Crohn’s disease) 6.9 1.9–24.4 0.002
 Smoking habit 0.3 0.09–1.2 0.09
(c) Adalimumab
 Adalimumab trough levels (μg/mL) 1.09 1.008–1.1 0.03
 Optimized dosage of infliximab 0.2 0.07–0.6 0.01
 Ulcerative colitis (vs. Crohn’s disease) 1.5 0.4–5.6 0.4
 Smoking habit 0.2 0.07–0.7 0.01
Fig. 2  Anti-TNF trough levels, infliximab (a) and adalimumab (b), in 
patients with mucosal healing versus those with endoscopically active 
disease
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after losing response. Therefore, some of these patients 
could have lost response to the treatment either due to phar-
macokinetic issues (where the escalation of the treatment 
would be the most beneficial choice) or due to pharmaco-
dynamic problems. Thus, although patients under escalated 
dosage had higher anti-TNF levels than patients with stand-
ard dosage, the probability of having mucosal healing was 
lower.
Our study has some limitations. First of all, only patients 
with luminal CD were evaluated. Some authors suggested 
that patients with perianal CD need higher anti-TNF lev-
els to reach remission. We could not provide data on this 
specific clinical scenario. However, the heterogeneity in the 
treatment of perianal disease (mainly due to the differences 
in the surgical approach to perianal fistula) would have cre-
ated bias, making the interpretation of the results difficult. 
Moreover, there was a lack of centralized reading of endo-
scopic images in our study. However, all examinations were 
performed by endoscopists with wide experience in IBD, 
who were indeed responsible for those procedures in their 
centers.
Our study has several strengths. To the best of our knowl-
edge, up to now, this is the largest prospective study evalu-
ating the correlation between anti-TNF trough levels and 
mucosal healing (which should be the therapeutic goal) in 
the clinical practice setting. In fact, patients with incomplete 
ileocolonoscopies or those with affected intestinal segments 
non-accessible to endoscopy were excluded from the study. 
Furthermore, we have included a very homogeneous popula-
tion of patients receiving anti-TNF drugs in the maintenance 
phase (not during the induction).
In conclusion, there is a relationship between infliximab 
and adalimumab trough levels, and mucosal healing in IBD 
patients. Nevertheless, the accuracy of the determination of 
anti-TNF serum concentrations able to predict mucosal heal-
ing is poor (AUC < 0.7), meaning that a high proportion of 
patients would be misclassified based on anti-TNF serum 
levels. The best cutoff values for predicting mucosal heal-
ing are 3.4 and 7.2 μg/mL for infliximab and adalimumab, 
respectively. However, due to the low accuracy of the test, 
the results should be interpreted with caution in clinical 
practice. In addition, we have identified that smoking habit, 
having CD (vs. UC), and to be treated with escalated dosage 
Table 4  Published studies assessing the correlation between infliximab and adalimumab serum levels and mucosal healing in inflammatory 
bowel disease patients under maintenance treatment
ADA adalimumab, AUC area under the curve, CD Crohn’s disease, IFX infliximab, N number of patients, P prospective, P-H post hoc, R retro-
spective, UC ulcerative colitis, CD Crohn’s disease
References Design N Anti-TNF Assay Endoscopic 
activity index
AUC Cutoff Variables inde-
pendently associ-
ated with mucosal 
healing
Imaeda et al. 
[16]
P 45 CD (78 
endosco-
pies)
IFX ELISA Modified Rut-
geerts scoring 
system
0.63 4 μg/mL –
Roblin et al. 
[17]
P 22CD
18 UC
ADA ELISA Absence of 
ulcerations
0.77 4.9 μg/mL ADA trough lev-
els and duration 
of treatment
Reinisch et al. 
[18]
P–H 123 CD IFX Sandwich 
enzyme 
immunoassay
Absence of 
ulcerations 
and erosions
0.63 3 μg/mL C-reactive protein 
normalization 
and IFX trough 
levels
Zittan et al. [19] P 60 CD ADA (no trough 
levels)
Liquid phase 
mobility shift 
assay
Absence of 
ulcerations
– 4 μg/mL Harvey-Bradshaw 
index score and 
ADA levels
Yarur et al. [20] P 59 CD
7 UC
ADA (no trough 
levels)
Homogeneous 
mobility shift 
assay
Lack of inflam-
matory find-
ings
0.76 7.8 μg/mL –
Ungar et al. [21] R 111 CD
34 UC
ADA
IFX (no trough 
levels)
Capture 
enzyme-linked 
immunoab-
sorbent assay
SES-CD < 3 
or endo-
scopic Mayo 
score ≤ 1
ADA: 0.7
IFX: 0.75
ADA: 8–12 μg/
mL
IFX: 6–10 μg/
mL
Serum IFX levels. 
Serum ADA 
levels and epi-
sodic treatment
Morita et al. 
[22]
P 42 CD ADA ELISA Modified Rut-
geerts scoring 
system
0.79 7.9 μg/mL –
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of anti-TNF were independently associated with lower prob-
ability of mucosal healing. We believe that this large pro-
spective study provides valuable information that can help 
with decision making in therapeutic drug monitoring setting.
Acknowledgments The authors wish to thank Sanquin for analyzing 
serum samples.
Author’s contribution M. Chaparro and J.P. Gisbert conceived and 
designed this study. All the authors participated in the collection of 
data and samples of patients. M. Chaparro and J.P. Gisbert analyzed 
and interpreted the results and wrote the manuscript. All the authors 
critically reviewed the manuscript, and have read and approved the final 
version of the manuscript.
Funding This research was funded by grants from the Instituto de 
Salud Carlos III (FIS.12/02557 and PI13/00041) and the Ministerio 
de Economía (SAF2014-56642-JIN) from the Spanish Government.
Compliance with ethical standards 
Conflict of interest María Chaparro has served as a speaker, or has 
received research or education funding from MSD, AbbVie, Hospi-
ra, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk 
Pharma, and Tillotts Pharma. Manuel Barreiro-de Acosta has served 
as a speaker, has served as a consultant and advisory member for, or 
has received research funding from MSD, AbbVie, Hospira, Takeda, 
Janssen, Kern, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk 
Pharma, Chiesi, Gebro Pharma, Otsuka Pharmaceuticals, and Tillotts 
Pharma. Maribel Vera has served as speaker for Pfizer and a consult-
ant and advisory member for Kern Pharma. Iván Guerra has served 
as speaker for Pfizer and a consultant and advisory member for Kern 
Pharma. Carlos Taxonera has served as a speaker, or a consultant and 
advisory member for MSD, AbbVie, Hospira, Pfizer, Takeda, Janssen, 
Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, and Ge-
bro Pharma. Xavier Calvet has received grants for research from Ab-
bott, MSD, Vifor fees for advisory boards form Abbott, MSD, Takeda 
and Vifor and has given lectures for Abbott, MSD, Takeda, Shire and 
Allergan. Rocío Ferreiro-Iglesias has served as a speaker for AbbVie, 
Shire y MSD. Javier P. Gisbert has served as a speaker, has served as a 
consultant and advisory member for, or has received research funding 
from MSD, AbbVie, Hospira, Pfizer, Kern Pharma, Biogen, Takeda, 
Janssen, Roche, Celgene, Ferring, Faes Farma, Shire Pharmaceuticals, 
Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, 
Otsuka Pharmaceutical, Vifor Pharma. The remaining authors declare 
that they have no conflict of interest.
References
 1. Chaparro M, Panes J, Garcia V, et al. Long-term durability of 
infliximab treatment in Crohn’s disease and efficacy of dose 
“escalation” in patients losing response. J Clin Gastroenterol. 
2011;45:113–118.
 2. Chaparro M, Panes J, Garcia V, et al. Long-term durability of 
response to adalimumab in Crohn’s disease. Inflamm Bowel Dis. 
2012;18:685–690.
 3. Gisbert JP, Panes J. Loss of response and requirement of inflixi-
mab dose intensification in Crohn’s disease: a review. Am J Gas-
troenterol. 2009;104:760–767.
 4. Chaparro M, Guerra I, Munoz-Linares P, et al. Systematic review: 
antibodies and anti-TNF-alpha levels in inflammatory bowel dis-
ease. Aliment Pharmacol Ther. 2012;35:971–986.
 5. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough con-
centrations of infliximab guide dosing for patients with inflam-
matory bowel disease. Gastroenterology. 2015;148:e1323.
 6. D’Haens G, Vermeire S, Lambrecht G, et al. OP029 Drug-con-
centration versus symptom-driven dose adaptation of Infliximab 
in patients with active Crohn’s disease: a prospective, randomised, 
multicentre trial (Tailorix). J Crohns Colitis. 2016;10:S24.
 7. Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gas-
troenterological Association Institute Clinical Guidelines C. 
American Gastroenterological Association Institute Guideline 
on therapeutic drug monitoring in inflammatory bowel disease. 
Gastroenterology. 2017;153:827–834.
 8. Gomollon F, Dignass A, Annese V, et al. 3rd European evi-
dence-based consensus on the diagnosis and management of 
Crohn’s disease 2016: part 1: diagnosis and medical manage-
ment. J Crohns Colitis. 2017;11:3–25.
 9. Steenholdt C, Ainsworth MA, Tovey M, et  al. Compari-
son of techniques for monitoring infliximab and antibod-
ies against infliximab in Crohn’s disease. Ther Drug Monit. 
2013;35:530–538.
 10. Vande Casteele N, Buurman DJ, Sturkenboom MG, et  al. 
Detection of infliximab levels and anti-infliximab antibodies: a 
comparison of three different assays. Aliment Pharmacol Ther. 
2012;36:765–771.
 11. Peyrin-Biroulet L, Sandborn W, Sands BE, et  al. Selecting 
therapeutic targets in inflammatory bowel disease (STRIDE): 
determining therapeutic goals for treat-to-target. Am J Gastro-
enterol. 2015;110:1324–1338.
 12. Harris PA, Taylor R, Thielke R, et al. Research electronic data 
capture (REDCap)—a metadata-driven methodology and work-
flow process for providing translational research informatics 
support. J Biomed Inform. 2009;42:377–381.
 13. Daperno M, D’Haens G, Van Assche G, et  al. Develop-
ment and validation of a new, simplified endoscopic activity 
score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 
2004;60:505–512.
 14. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of 
the postoperative course of Crohn’s disease. Gastroenterology. 
1990;99:956–963.
 15. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid 
enema in the treatment of distal ulcerative colitis, proctosigmoidi-
tis, and proctitis. Gastroenterology. 1987;92:1894–1898.
 16. Imaeda H, Bamba S, Takahashi K, et al. Relationship between 
serum infliximab trough levels and endoscopic activities in 
patients with Crohn’s disease under scheduled maintenance treat-
ment. J Gastroenterol. 2014;49:674–682.
 17. Roblin X, Marotte H, Rinaudo M, et al. Association between 
pharmacokinetics of adalimumab and mucosal healing in patients 
with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 
2014;12:e82.
 18. Reinisch W, Colombel JF, Sandborn WJ, et al. Factors associ-
ated with short- and long-term outcomes of therapy for Crohn’s 
disease. Clin Gastroenterol Hepatol. 2015;13:e532.
 19. Zittan E, Kabakchiev B, Milgrom R, et al. Higher adalimumab 
drug levels are associated with mucosal healing in patients with 
Crohn’s disease. J Crohns Colitis. 2016;10:510–515.
 20. Yarur AJ, Jain A, Hauenstein SI, et al. Higher adalimumab lev-
els are associated with histologic and endoscopic remission in 
patients with Crohn’s disease and ulcerative colitis. Inflamm 
Bowel Dis. 2016;22:409–415.
Digestive Diseases and Sciences 
1 3
 21. Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-alpha 
therapy: serum levels of infliximab and adalimumab are associ-
ated with mucosal healing in patients with inflammatory bowel 
diseases. Clin Gastroenterol Hepatol. 2016;14:e552.
 22. Morita Y, Imaeda H, Nishida A, et  al. Association between 
serum adalimumab concentrations and endoscopic disease activ-
ity in patients with Crohn’s disease. J Gastroenterol Hepatol. 
2016;31:1831–1836.
 23. Hindryckx P, Novak G, Vande Casteele N, et al. Review article: 
dose optimisation of infliximab for acute severe ulcerative colitis. 
Aliment Pharmacol Ther. 2017;45:617–630.
 24. Nunes T, Etchevers MJ, Domenech E, et al. Smoking does influ-
ence disease behaviour and impacts the need for therapy in 
Crohn’s disease in the biologic era. Aliment Pharmacol Ther. 
2013;38:752–760.
Affiliations
María Chaparro1,18 · Manuel Barreiro-de Acosta2 · Ana Echarri3 · Rosendo Almendros4 · Jesús Barrio5 · Jordina Llao6 · 
Fernando Gomollón7,18 · Maribel Vera8 · José Luis Cabriada9 · Jordi Guardiola10 · Iván Guerra11 · Belén Beltrán12,18 · 
Oscar Roncero13 · David Busquets14 · Carlos Taxonera15 · Xavier Calvet16,18 · Rocío Ferreiro-Iglesias2 · 
Virginia Ollero Pena3 · David Bernardo1,18 · María G. Donday1,18 · Ana Garre1,18 · Ana Godino17 · Ana Díaz17 · 
Javier P. Gisbert1,18
1 Servicio de Aparato Digestivo, Hospital Universitario de La 
Princesa e Instituto de Investigación Sanitaria Princesa (IIS-
IP), Madrid, Spain
2 Servicio de Aparato Digestivo, Hospital Clínico Universitario 
de Santiago, Santiago de Compostela, Spain
3 Servicio de Aparato Digestivo, Complejo Hospitalario 
Universitario de Ferrol, Coruña, Spain
4 Servicio de Farmacia, Hospital Universitario Rio Hortega, 
Valladolid, Spain
5 Servicio de Aparato Digestivo, Hospital Universitario Rio 
Hortega, Valladolid, Spain
6 Servicio de Aparato Digestivo, Hospital de la Santa Creu i 
Sant Pau, Barcelona, Spain
7 Servicio de Aparato Digestivo, Hospital Clínico Universitario 
Lozano Blesa and IIS-Aragón, Saragossa, Spain
8 Servicio de Aparato Digestivo, Hospital Universitario Puerta 
de Hierro, Majadahonda, Spain
9 Servicio de Aparato Digestivo, Hospital Galdakao-Usansolo, 
Vizcaya, Spain
10 Servicio de Aparato Digestivo, Hospital Universitari de 
Bellvitge-IDIBELL, Universidad de Barcelona, Barcelona, 
Spain
11 Servicio de Aparato Digestivo, Hospital Universitario de 
Fuenlabrada, Madrid, Spain
12 Servicio de Aparato Digestivo, Hospital Universitari La Fe, 
Valencia, Spain
13 Servicio de Aparato Digestivo, Complejo Hospitalario la 
Mancha Centro, Ciudad Real, Spain
14 Servicio de Aparato Digestivo, Hospital Universitari de 
Girona Doctor Josep Trueta, Girona, Spain
15 Servicio de Aparato Digestivo, Hospital Clínico San Carlos 
and Instituto de Investigación del Hospital Clínico San Carlos 
(IdISSC), Madrid, Spain
16 Servicio de Aparato Digestivo, Corporació Sanitària Parc 
Taulí, Sabadell, Barcelona, Spain
17 Servicio de Análisis Clínicos, Hospital Universitario de 
La Princesa e Instituto de Investigación Sanitaria Princesa 
(IIS-IP), Madrid, Spain
18 Centro de Investigación Biomédica en Red de Enfermedades 
Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
